Skip to main content
Top
Published in: Diabetologia 7/2016

01-07-2016 | Article

Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial

Authors: Geraldine F. Clough, Keith G. McCormick, Eleonora Scorletti, Lokpal Bhatia, Philip C. Calder, Michael J. Griffin, Christopher D. Byrne

Published in: Diabetologia | Issue 7/2016

Login to get access

Abstract

Aims/hypothesis

The effect of n-3 fatty acid treatment on temperature perception as a sensory nerve function modality is uncertain. In patients with non-alcoholic fatty liver disease (NAFLD) both with and without type 2 diabetes, we: (1) tested whether 15–18 months’ treatment with 4 g/day of docosahexaenoic plus eicosapentaenoic acid (DHA+EPA) improved hot (HPT) and cold (CPT) temperature perception thresholds and (2) explored factors associated with HPT and CPT, in a randomised, double-blind, placebo-controlled trial.

Methods

The effect of treatment (n = 44) on HPT, CPT and temperature perception index (TPI: difference between HPT and CPT) was measured at the big toe in 90 individuals without neuropathy (type 2 diabetes; n = 30). Participants were randomised 1:1, using sequential numbering, by personnel independent from the trial team. All participants and all members of the research team were blinded to group assignment. Data were collected in the Southampton National Institute for Health Research Biomedical Research Centre. Treatment effects and the independence of associations were testing by regression modelling.

Results

Mean ± SD age was 50.9 ± 10.6 years. In men (n = 53) and women (n = 37), HPTs (°C) were 46.1 ± 5.1 and 43.1 ± 6.4 (p = 0.02), CPTs (°C) were 22.7 ± 3.4 and 24.5 ± 3.6 (p = 0.07) and TPIs (°C) were 23.4 ± 7.4 and 18.7 ± 9.5 (p = 0.008), respectively. In univariate analyses, total body fat percentage (measured by dual-energy x-ray absorptiometry [DXA]) was associated with HPT (r = –0.36 p = 0.001), CPT (r = 0.35 p = 0.001) and TPI (r = 0.39 p = 0.0001). In multivariable-adjusted regression models, adjusting for age, sex and other potential confounders, only body fat percentage was independently associated with HPT, CPT or TPI (p = 0.006, p = 0.006 and p = 0.002, respectively). DHA+EPA treatment did not modify HPT, CPT or TPI (p = 0.93, p = 0.44 and p = 0.67, respectively). There were no important adverse effects or side effects reported.

Conclusions/interpretation

Higher body fat percentage is associated with enhanced temperature perception. There was no benefit of treatment with high-dose n-3 fatty acids on the thresholds to detect hot or cold stimuli.

Trial registration:

ClinicalTrials.gov NCT00760513

Funding:

This work was supported by the National Institute for Health Research through the NIHR Southampton Biomedical Research Unit grant and by a Diabetes UK allied health research training fellowship awarded to KMcC (Diabetes UK. BDA 09/0003937).
Appendix
Available only for authorised users
Literature
1.
go back to reference Karvestedt L, Martensson E, Grill V et al (2011) The prevalence of peripheral neuropathy in a population-based study of patients with type 2 diabetes in Sweden. J Diabet Complications 25:97–106CrossRef Karvestedt L, Martensson E, Grill V et al (2011) The prevalence of peripheral neuropathy in a population-based study of patients with type 2 diabetes in Sweden. J Diabet Complications 25:97–106CrossRef
2.
go back to reference Tesfaye S, Boulton AJ, Dickenson AH (2013) Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 36:2456–2465CrossRefPubMedCentralPubMed Tesfaye S, Boulton AJ, Dickenson AH (2013) Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 36:2456–2465CrossRefPubMedCentralPubMed
3.
4.
go back to reference Karvestedt L, Martensson E, Grill V et al (2009) Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 32:317–322CrossRefPubMedCentralPubMed Karvestedt L, Martensson E, Grill V et al (2009) Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 32:317–322CrossRefPubMedCentralPubMed
5.
go back to reference Tesfaye S, Selvarajah D (2012) Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 28(Suppl 1):S8–S14CrossRef Tesfaye S, Selvarajah D (2012) Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 28(Suppl 1):S8–S14CrossRef
6.
go back to reference Krumova EK, Geber C, Westermann A, Maier C (2012) Neuropathic pain: is quantitative sensory testing helpful? Curr Diab Rep 12:393–402CrossRefPubMed Krumova EK, Geber C, Westermann A, Maier C (2012) Neuropathic pain: is quantitative sensory testing helpful? Curr Diab Rep 12:393–402CrossRefPubMed
7.
go back to reference Korei AE, Istenes I, Papanas N, Kempler P (2016) Small-fiber neuropathy: a diabetic microvascular complication of special clinical, diagnostic, and prognostic importance. Angiology 67:49–57CrossRefPubMed Korei AE, Istenes I, Papanas N, Kempler P (2016) Small-fiber neuropathy: a diabetic microvascular complication of special clinical, diagnostic, and prognostic importance. Angiology 67:49–57CrossRefPubMed
8.
go back to reference McCormick KG, Scorletti E, Bhatia L et al (2015) Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. Diabetologia 58:1916–1925CrossRefPubMed McCormick KG, Scorletti E, Bhatia L et al (2015) Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. Diabetologia 58:1916–1925CrossRefPubMed
9.
go back to reference Chao CC, Hsieh SC, Yang WS et al (2007) Glycemic control is related to the severity of impaired thermal sensations in type 2 diabetes. Diabetes Metab Res Rev 23:612–620CrossRefPubMed Chao CC, Hsieh SC, Yang WS et al (2007) Glycemic control is related to the severity of impaired thermal sensations in type 2 diabetes. Diabetes Metab Res Rev 23:612–620CrossRefPubMed
10.
go back to reference Shukla G, Bhatia M, Behari M (2005) Quantitative thermal sensory testing—value of testing for both cold and warm sensation detection in evaluation of small fiber neuropathy. Clin Neurol Neurosurg 107:486–490CrossRefPubMed Shukla G, Bhatia M, Behari M (2005) Quantitative thermal sensory testing—value of testing for both cold and warm sensation detection in evaluation of small fiber neuropathy. Clin Neurol Neurosurg 107:486–490CrossRefPubMed
11.
go back to reference Hafner J, Lee G, Joester J et al (2015) Thermal quantitative sensory testing: a study of 101 control subjects. J Clin Neurosci 22:588–591CrossRefPubMed Hafner J, Lee G, Joester J et al (2015) Thermal quantitative sensory testing: a study of 101 control subjects. J Clin Neurosci 22:588–591CrossRefPubMed
12.
go back to reference Heldestad V, Linder J, Sellersjo L, Nordh E (2010) Reproducibility and influence of test modality order on thermal perception and thermal pain thresholds in quantitative sensory testing. Clin Neurophysiol 121:1878–1885CrossRefPubMed Heldestad V, Linder J, Sellersjo L, Nordh E (2010) Reproducibility and influence of test modality order on thermal perception and thermal pain thresholds in quantitative sensory testing. Clin Neurophysiol 121:1878–1885CrossRefPubMed
13.
go back to reference Moloney NA, Hall TM, Doody CM (2012) Reliability of thermal quantitative sensory testing: a systematic review. J Rehabil Res Dev 49:191–207CrossRefPubMed Moloney NA, Hall TM, Doody CM (2012) Reliability of thermal quantitative sensory testing: a systematic review. J Rehabil Res Dev 49:191–207CrossRefPubMed
14.
go back to reference Yuen KC, Baker NR, Rayman G (2002) Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 25:1699–1703CrossRefPubMed Yuen KC, Baker NR, Rayman G (2002) Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 25:1699–1703CrossRefPubMed
15.
go back to reference Patel N, Mishra V, Patel P, Dikshit RK (2014) A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. J Diabetes Metab Disord 13:62CrossRefPubMedCentralPubMed Patel N, Mishra V, Patel P, Dikshit RK (2014) A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. J Diabetes Metab Disord 13:62CrossRefPubMedCentralPubMed
17.
go back to reference Okuda Y, Mizutani M, Ogawa M et al (1996) Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. J Diabet Complications 10:280–287CrossRef Okuda Y, Mizutani M, Ogawa M et al (1996) Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. J Diabet Complications 10:280–287CrossRef
18.
go back to reference Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ (2000) Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 102:1264–1269CrossRefPubMed Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ (2000) Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 102:1264–1269CrossRefPubMed
19.
go back to reference Coste TC, Gerbi A, Vague P, Pieroni G, Raccah D (2003) Neuroprotective effect of docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy. Diabetes 52:2578–2585CrossRefPubMed Coste TC, Gerbi A, Vague P, Pieroni G, Raccah D (2003) Neuroprotective effect of docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy. Diabetes 52:2578–2585CrossRefPubMed
20.
go back to reference Scorletti E, Bhatia L, McCormick KG et al (2014) Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. Contemp Clin Trials 37:301–311CrossRefPubMed Scorletti E, Bhatia L, McCormick KG et al (2014) Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. Contemp Clin Trials 37:301–311CrossRefPubMed
21.
go back to reference Scorletti E, Bhatia L, McCormick KG, et al (2014) Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the Welcome* study. Hepatology 60:1211–1221 Scorletti E, Bhatia L, McCormick KG, et al (2014) Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the Welcome* study. Hepatology 60:1211–1221
22.
go back to reference Spruce MC, Bowling FL (2012) Diabetic foot screening: new technology versus 10 g monofilament. Int J Low Extrem Wounds 11:43–48CrossRefPubMed Spruce MC, Bowling FL (2012) Diabetic foot screening: new technology versus 10 g monofilament. Int J Low Extrem Wounds 11:43–48CrossRefPubMed
23.
go back to reference Seah SA, Griffin MJ (2008) Normal values for thermotactile and vibrotactile thresholds in males and females. Int Arch Occup Environ Health 81:535–543CrossRefPubMed Seah SA, Griffin MJ (2008) Normal values for thermotactile and vibrotactile thresholds in males and females. Int Arch Occup Environ Health 81:535–543CrossRefPubMed
25.
go back to reference Kuhtz-Buschbeck JP, Andresen W, Gobel S, Gilster R, Stick C (2010) Thermoreception and nociception of the skin: a classic paper of Bessou and Perl and analyses of thermal sensitivity during a student laboratory exercise. Adv Physiol Educ 34:25–34CrossRefPubMed Kuhtz-Buschbeck JP, Andresen W, Gobel S, Gilster R, Stick C (2010) Thermoreception and nociception of the skin: a classic paper of Bessou and Perl and analyses of thermal sensitivity during a student laboratory exercise. Adv Physiol Educ 34:25–34CrossRefPubMed
26.
go back to reference Miscio G, Guastamacchia G, Brunani A, Priano L, Baudo S, Mauro A (2005) Obesity and peripheral neuropathy risk: a dangerous liaison. J Peripher Nerv Syst 10:354–358CrossRefPubMed Miscio G, Guastamacchia G, Brunani A, Priano L, Baudo S, Mauro A (2005) Obesity and peripheral neuropathy risk: a dangerous liaison. J Peripher Nerv Syst 10:354–358CrossRefPubMed
27.
go back to reference Malik RA, Veves A, Walker D et al (2001) Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol 101:367–374PubMed Malik RA, Veves A, Walker D et al (2001) Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol 101:367–374PubMed
28.
go back to reference Dziemidok P, Szczesniak G, Kostrzewa-Zablocka E, Paprzycki P, Korzon-Burakowska A (2012) Current glycaemic control has no impact on the advancement of diabetic neuropathy. Ann Agric Environ Med 19:742–745PubMed Dziemidok P, Szczesniak G, Kostrzewa-Zablocka E, Paprzycki P, Korzon-Burakowska A (2012) Current glycaemic control has no impact on the advancement of diabetic neuropathy. Ann Agric Environ Med 19:742–745PubMed
29.
go back to reference Crawford F, Inkster M, Kleijnen J, Fahey T (2007) Predicting foot ulcers in patients with diabetes: a systematic review and meta-analysis. QJM 100:65–86CrossRefPubMed Crawford F, Inkster M, Kleijnen J, Fahey T (2007) Predicting foot ulcers in patients with diabetes: a systematic review and meta-analysis. QJM 100:65–86CrossRefPubMed
30.
go back to reference Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M (2003) The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60:108–111CrossRefPubMed Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M (2003) The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60:108–111CrossRefPubMed
31.
go back to reference Hagander LG, Midani HA, Kuskowski MA, Parry GJ (2000) Quantitative sensory testing: effect of site and pressure on vibration thresholds. Clin Neurophysiol 111:1066–1069CrossRefPubMed Hagander LG, Midani HA, Kuskowski MA, Parry GJ (2000) Quantitative sensory testing: effect of site and pressure on vibration thresholds. Clin Neurophysiol 111:1066–1069CrossRefPubMed
32.
go back to reference Seah SA, Griffin MJ (2010) Thermotactile thresholds at the fingertip: effect of contact area and contact location. Somatosens Mot Res 27:82–92CrossRefPubMed Seah SA, Griffin MJ (2010) Thermotactile thresholds at the fingertip: effect of contact area and contact location. Somatosens Mot Res 27:82–92CrossRefPubMed
34.
go back to reference Backonja MM, Walk D, Edwards RR et al (2009) Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory abnormalities. Clin J Pain 25:641–647CrossRefPubMed Backonja MM, Walk D, Edwards RR et al (2009) Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory abnormalities. Clin J Pain 25:641–647CrossRefPubMed
35.
go back to reference Polydefkis M, Arezzo J, Nash M et al (2015) Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy. J Peripher Nerv Syst 20:363–371CrossRefPubMed Polydefkis M, Arezzo J, Nash M et al (2015) Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy. J Peripher Nerv Syst 20:363–371CrossRefPubMed
36.
go back to reference Guha IN, Parkes J, Roderick P et al (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47:455–460CrossRefPubMed Guha IN, Parkes J, Roderick P et al (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47:455–460CrossRefPubMed
Metadata
Title
Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial
Authors
Geraldine F. Clough
Keith G. McCormick
Eleonora Scorletti
Lokpal Bhatia
Philip C. Calder
Michael J. Griffin
Christopher D. Byrne
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-3966-8

Other articles of this Issue 7/2016

Diabetologia 7/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.